A new primate model for the study of intravenous thrombotic potential and its modification.
Advances in venous reconstruction have been limited by inherent venous thrombogenicity and the absence of a suitable prosthetic material for use in the venous system. We have designed an in vivo experimental model to evaluate early blood-material interactions within the venous system and to quantitate drug efficacy in the alteration of platelet function and fibrin deposition in the baboon. An 8F catheter was placed percutaneously in the femoral vein of an adult male baboon. Indium 111-labeled autogenous platelets or iodine 125-labeled human fibrinogen was infused before the introduction, into the inferior vena cava, of a linear array of 5 x 15 mm alternating Dacron and polytetrafluoroethylene samples attached to a benzalkonium-heparin-treated guide wire. At 60 or 120 minutes the samples were removed and a 1 ml aliquot of blood was drawn. The materials and blood samples were counted in a gamma well counter, and the material counts were normalized to the circulating label present in the 1 ml blood sample. The experiment was repeated after pretreatment with heparin, aspirin, or dextran. Whole blood clotting times and bleeding times were monitored. The results showed decreased platelet and fibrin deposition on polytetrafluoroethylene when compared with Dacron in the venous system. Aspirin, heparin, and dextran were all found to decrease platelet and fibrin deposition onto intravenously placed graft material samples (p less than 0.05, Student's t test). The data confirm the ability of the model to evaluate quantitatively anticoagulants, antiplatelet agents, and prospective graft materials for use in venous reconstructions.
Shoenfeld
N A
NA
Department of Surgery, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111.
Yeager
A
A
Connolly
R
R
Ramberg
K
K
Forgione
L
L
Giorgio
A
A
Valeri
C R
CR
Callow
A D
AD
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets; D001807:Blood Vessel Prosthesis; D003911:Dextrans / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006493:Heparin / Q000627:therapeutic use; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D008297:Male; D008422:Materials Testing; D010215:Papio; D010974:Platelet Aggregation / Q000187:drug effects; D011093:Polyethylene Terephthalates; D011138:Polytetrafluoroethylene; D013927:Thrombosis / Q000517:prevention & control*
D003911:Dextrans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D011093:Polyethylene Terephthalates; D011138:Polytetrafluoroethylene; D006493:Heparin; D001241:Aspirin